U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07523282) titled 'Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases' on April 03.
Brief Summary: This is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc).
Study Start Date: April 28
Study Type: INTERVENTIONAL
Condition:
Autoimmune Disease
Intervention:
DRUG: HN2302 Injection
Dosing will begin at a lower dose level and may be escalated to dose levels considered safe and potentially effective according to the study protocol.
Recruitment Status: NOT_YET_REC...